Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 5/2021

01-05-2021 | Stroke | Original Article

Ischemic stroke/transient ischemic attack in adults with primary immune thrombocytopenia: a meta-analysis

Authors: Lishou Pan, Huilin Leng, Yin Huang, Ningyan Xia, Lingjin Jin, Han-Ting Zhang

Published in: Neurological Sciences | Issue 5/2021

Login to get access

Abstract

Objective

To carry out a systematic review to help resolve the controversy of ischemic stroke (IS)/transient ischemic attack (TIA) in patients with primary immune thrombocytopenia (ITP).

Methods

A database search of PubMed and Ovid Embase was conducted for epidemiologic studies published up to December 17, 2019. The effective size was estimated by pooled prevalence, annualized incidence/risk, relative risk (RR), and their corresponding 95% confidence intervals (CIs).

Results

The systematic review included 14 eligible studies from 11 publications. The pooled annualized cumulative incidence was 0.15% (95% CI, 0.03–0.26%) per person-years. And the pooled annualized cumulative risk of IS/TIA of ITP was 0.86% (95% CI, 0.33–1.39%) per year based on 3 population-based cohort studies. There was a higher risk of incident IS/TIA in ITP patients than ITP-free subjects (pooled unadjusted or adjusted RR with 95% CI, 1.46 [1.22–1.74] or 1.50 [1.29–1.73]).

Conclusions

IS/TIA was not uncommon in patients with primary ITP. ITP patients have a higher risk of IS/TIA compared with the reference cohorts. Healthcare professionals should take into account the risk of IS/TIA when treating ITP patients with or without a history of IS/TIA.
Appendix
Available only for authorised users
Literature
1.
Cooper N, Ghanima W (2019) Immune thrombocytopenia. N Engl J Med 381(10):945–955PubMed
2.
Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN (2010) The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 85(3):174–180PubMed
3.
Mihalov J, Timarova G (2016) A seeming paradox: ischemic stroke in the context of idiopathic thrombocytopenic purpura. Clinical & Applied Thrombosis/Hemostasis 22(2):115–120
4.
Furlan JC, Fang J, Silver FL (2016) Outcomes after acute ischemic stroke in patients with thrombocytopenia or thrombocytosis. J Neurol Sci 362:198–203PubMed
5.
Fogarty PF, Segal JB (2007) The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol 14(5):515–519PubMed
6.
Ekstrand C, Linder M, Baricault B, Lafaurie M, Sailler L, Lapeyre-Mestre M, Kieler H, Moulis G, Bahmanyar S (2019) Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - results from two nationwide cohorts. Thromb Res 178:124–131PubMed
7.
Jy W, Horstman LL, Arce M, Ahn YS (1992) Clinical significance of platelet microparticles in autoimmune thrombocytopenias. Journal of Laboratory & Clinical Medicine 119(4):334–345
8.
Sewify EM, Sayed D, Abdel Aal RF, Ahmad HM, Abdou MA (2013) Increased circulating red cell microparticles (RMP) and platelet microparticles (PMP) in immune thrombocytopenic purpura. Thromb Res 131(2):e59–e63PubMed
9.
Davizon P, Lopez JA (2009) Microparticles and thrombotic disease. Curr Opin Hematol 16(5):334–341PubMed
10.
Chandan JS, Thomas T, Lee S, Marshall T, Willis B, Nirantharakumar K, Gill P (2018) The association between idiopathic thrombocytopenic purpura and cardiovascular disease: a retrospective cohort study. Journal of Thrombosis & Haemostasis 16(3):474–480
11.
Nørgaard M, Cetin K, Maegbaek ML, Kristensen NR, Ghanima W, Bahmanyar S, Stryker S, Christiansen CF (2016) Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol 174(4):639–642PubMed
12.
Enger C, Bennett D, Forssen U, Fogarty PF, McAfee AT (2010) Comorbidities in patients with persistent or chronic immune thrombocytopenia. Int J Hematol 92(2):289–295PubMed
13.
Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, Sanderson S, Provan D (2010) Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom general practice research database. Haematologica 95(7):1167–1175PubMedPubMedCentral
14.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Jama 283(15):2008–2012PubMed
15.
Zeng X, Zhang Y, Kwong JS et al (2015) The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 8(1):2–10PubMed
16.
17.
Nyaga VN, Arbyn M, Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72(1):39PubMedPubMedCentral
18.
Harris RJ, Deeks JJ, Altman DG, Bradburn MJ, Harbord RM, Sterne JA (2008) Metan: fixed-and random-effects meta-analysis. Stata J 8(1):3–28
19.
20.
Borenstein M, Hedges LV, Higgins JP, Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 1(2):97–111PubMed
21.
Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23(9):1351–1375PubMed
22.
Zhang T, Zhong W (2012) Applied methodology for evidence-based medicine. Central South University Press, Changsha, Hunan Province
23.
Nørgaard M, Jensen AO, Engebjerg MC, Farkas DK, Thomsen RW, Cha S, Zhao S, Sørensen HT (2011) Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood 117(13):3514–3520PubMed
24.
Sinkovic A, Majal M (2015) The impact of thrombocytopenia on outcome in patients with acute coronary syndromes: a single center retrospective study. Biomed Res Int 2015:907304PubMedPubMedCentral
25.
Moret C, Tichelli A, Wieland-Greguare-Sander A, Angelillo-Scherrer A, Rovo A (2017) Prevalence and risk factors for thrombosis in adult ITP patients. Haematologica 102 (supplement 2): 594
26.
Sico JJ, Phipps MS, Concato J, Wells CK, Lo AC, Nadeau SE, Williams LS, Peixoto AJ, Gorman M, Boice JL, Bravata DM (2013) Thrombocytopenia and in-hospital mortality risk among ischemic stroke patients. Journal of Stroke & Cerebrovascular Diseases 22(7):e99–e102
27.
Ekstrand C, Baricault B, Linder M, et al. (2017) Prevalence of cardiovascular risk factors and incidence of venous and arterial thrombosis in non-splenectomized immune thrombocytopenia adult patients in sweden and france. results from two nationwide studies. Blood Conference: 59th Annual Meeting of the American Society of Hematology, ASH 130 (Supplement 1)
28.
Yang YJ, Yun GW, Song IC, Baek SW, Lee KS, Ryu HW, Lee MW, Lee HJ, Yun HJ, Kim S, Jo DY (2011) Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. Korean J Intern Med 26(4):449–454PubMedPubMedCentral
29.
Pierrot-Deseilligny Despujol C, Michel M, Khellaf M, Gouault M, Intrator L, Bierling P, Godeau B (2008) Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol 142(4):638–643PubMed
30.
Stasi R, Stipa E, Masi M, Cecconi M, Scimò MT, Oliva F, Sciarra A, Perrotti AP, Adomo G, Amadori S, Papa G (1995) Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 98(5):436–442PubMed
31.
Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR (2003) Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 122(6):966–974PubMed
32.
Jimenez JJ, Jy W, Mauro LM, Horstman LL, Fontana V, Ahn YS (2008) Transendothelial migration of leukocytes is promoted by plasma from a subgroup of immune thrombocytopenic purpura patients with small-vessel ischemic brain disease. Am J Hematol 83(3):206–211PubMed
33.
Kaya E, Erkurt MA, Aydogdu I, Kuku I, Ozhan O, Oner RI, Ulutas O (2007) Retrospective analysis of patients with idiopathic thrombocytopenic purpura from eastern Anatolia. Med Prin Pract 16(2):100–106
34.
Bidot L, Jy W, Bidot C Jr, Jimenez JJ, Fontana V, Horstman LL, Ahn YS (2008) Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis. Journal of Thrombosis & Haemostasis 6(6):913–919
35.
Moulis G, Baricault B, Ekstrand C, et al. (2018) Risk factors of thrombosis in adults with primary immune thrombocytopenia. a french nationwide cohort study. Blood Conference: 60th Annual Meeting of the American Society of Hematology, ASH 132 (Suppl. 1)
36.
Enger C, Bennett D, Forssen U, McAfee AT (2009) Risk of thromboembolic events among persons with chronic idiopathic thrombocytopenia purpura. Pharmacoepidem DRS 18(S1):S217
37.
Feudjo-Tepie MA, Le Roux G, Beach KJ, Bennett D, Robinson NJ (2009) Comorbidities of idiopathic thrombocytopenic purpura: a population-based study. Adv Hematol 2009:963506PubMedPubMedCentral
38.
Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J (2004) Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 76(3):205–213PubMed
39.
Machin N, Ragni MV, Comer DM, Yabes JG (2018) Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: an NIS study. Thromb Res 172:80–85PubMed
40.
Diz-Küçükkaya R, Hacıhanefioğlu A, Yenerel M, Turgut M, Keskin H, Nalçacı M, Īnanç M (2001) Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 98(6):1760–1764PubMed
41.
Gadenstatter M, Lamprecht B, Klingler A, Wetscher GJ, Greil R, Schmid T (2002) Splenectomy versus medical treatment for idiopathic thrombocytopenic purpura. Am J Surg 184(6):606–609 discussion 609-610PubMed
42.
Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS (2013) Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol 161(5):706–714PubMed
43.
Ruggeri M, Tosetto A, Palandri F, Polverelli N, Mazzucconi MG, Santoro C, Gaidano G, Lunghi M, Zaja F, de Stefano V, Sartori R, Fazi P, Rodeghiero F, the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Anemia and Thrombocytopenias Working Party. GIMEMA Study ITP0311 (2014) Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. Journal of Thrombosis & Haemostasis 12(8):1266–1273
44.
Khare S (2016) Risk factors of transient ischemic attack: an overview. J Mid-life Health 7(1):2–7
45.
Weimar C, Diener HC, Alberts MJ, Steg PG, Bhatt DL, Wilson PW, Mas JL, Röther J, REduction of Atherothrombosis for Continued Health Registry Investigators (2009) The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for continued health (REACH) registry. Stroke 40(2):350–354PubMed
46.
Lee YJ, Jy W, Horstman LL, Janania J, Reyes Y, Kelley RE, Ahn YS (1993) Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 72(4):295–304PubMed
47.
Ichijo M, Ishibashi S, Ohkubo T, Nomura S, Sanjo N, Yokota T, Mizusawa H (2014) Elevated platelet microparticle levels after acute ischemic stroke with concurrent idiopathic thrombocytopenic purpura. Journal of Stroke & Cerebrovascular Diseases 23(3):587–589
48.
Thachil J, Callaghan T, Martlew V (2010) Thromboembolic events are not uncommon in patients with immune thrombocytopenia. Br J Haematol 150(4):496–497PubMed
Metadata
Title
Ischemic stroke/transient ischemic attack in adults with primary immune thrombocytopenia: a meta-analysis
Authors
Lishou Pan
Huilin Leng
Yin Huang
Ningyan Xia
Lingjin Jin
Han-Ting Zhang
Publication date
01-05-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 5/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04746-2

Other articles of this Issue 5/2021

Neurological Sciences 5/2021 Go to the issue

COVID-19

Factors affecting the behavior of children with ASD during the first outbreak of the COVID-19 pandemic

Original Article

Effects of N-Pep-12 dietary supplementation on neurorecovery after ischemic stroke

Original Article

Discovery of specific mutations in spinal muscular atrophy patients by next-generation sequencing

Brief Communication

ALS2-related disorders in Spanish children

Original Article

Evaluation of clinical findings and neurofibromatosis type 1 bright objects on brain magnetic resonance images of 60 Turkish patients with NF1 gene variants

COVID–19

Selective cranial multineuritis in severe COVID-19 pneumonia: two cases and literature review